Almost certainly no trials. I only reference this as in the December 22 newsletter Wolgen unambiguously stated that 23 would see the “first results of parvys, phimelanotide as novel molecules used for topical applications.”
But remember the dismal share price is due to shorters and global events and nothing to do with hopeless execution and consistent failure to hit any timeline. The number one priority should clearly be retention of current management given they have done such a fantastic job of growing the company in the last 4 years.
- Forums
- ASX - By Stock
- Ann: Chair Elect Letter
Almost certainly no trials. I only reference this as in the...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
|
|||||
Last
$14.59 |
Change
-0.150(1.02%) |
Mkt cap ! $730.6M |
Open | High | Low | Value | Volume |
$14.74 | $14.77 | $14.50 | $504.1K | 34.46K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 132 | $14.59 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.64 | 96 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 132 | 14.590 |
2 | 819 | 14.560 |
1 | 1000 | 14.550 |
1 | 133 | 14.530 |
1 | 600 | 14.510 |
Price($) | Vol. | No. |
---|---|---|
14.640 | 96 | 1 |
14.750 | 2156 | 4 |
14.770 | 133 | 1 |
14.790 | 133 | 1 |
14.820 | 133 | 1 |
Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online